From Cutting-Edge Research to Industry: Focused Energy Plans Spin-Off of Sourcelight
10.6.2026 11:38:00 CEST | Business Wire | Press release
Following its successful USD 240 million financing round, Focused Energy is continuing to systematically advance the industrialization of laser fusion as its core business. At the same time, the company plans to consolidate its activities in the field of laser-driven radiation sources into an independent entity under the name Sourcelight.
With this move, Focused Energy is laying the groundwork for the industrial transfer of selected technological building blocks emerging from its laser fusion development. The spin-off demonstrates how cutting-edge research can give rise to new industry: scientific excellence is translated into industrial applications with strong value creation and growth potential.
Sourcelight is intended to bring the LDRS (Laser-Driven Radiation Sources) technology developed by Focused Energy into targeted industrial applications. The technology combines laser-driven high-energy X-rays and neutrons in a single system. This enables not only high-resolution imaging, but also additional insights into material composition—particularly in areas where current inspection methods still face limitations in penetration depth, resolution, material identification, or operational flexibility.
Focused Energy sees relevant fields of application in the characterization and qualification of nuclear waste, in security and customs inspections at container ports, in industrial quality assurance, and in the non-destructive testing of safety-critical components. In all of these areas, demand is growing for methods that can penetrate deeply into materials, operate non-invasively, and at the same time provide additional information about internal structures and material composition.
The technological foundations date back to work by Focused Energy co-founder Prof. Markus Roth and colleagues on laser-driven particle acceleration in the early 2010s. A key milestone in the industrial orientation of this work is the collaborative PLANET project, led by Focused Energy and launched in 2024 together with partners from industry and research.
Technology Transfer with a Dedicated Focus
With the planned spin-off, Focused Energy is creating a clear structure to drive industrial applications of this technology forward in parallel with the long-term development of laser fusion.
"Focused Energy is pursuing the goal of making laser fusion industrially viable with full force. At the same time, technologies are emerging along this path that can generate tangible industrial impact at an earlier stage. Sourcelight is our way of clearly structuring and purposefully advancing this application perspective for laser-driven radiation sources," explains Thomas Forner, CEO and co-founder of Focused Energy.
"With Biblis—where we are also building the world’s first laser fusion power plant—we have a location with tremendous potential and visibility. It is also where the first industrial prototype of the LDRS technology is being developed. This will allow us to repeatedly demonstrate in Biblis how research can be translated into tangible industrial value creation, jobs, new technologies, and new companies. That is a strong message for Germany as a center of innovation."
Where Conventional Inspection Methods Reach Their Limits
LDRS describes the approach of using high-power lasers to provide compact sources of high-energy X-rays and fast neutrons. The technology opens up new possibilities for the non-destructive characterization of large components, closed containers, and complex material structures from the outside.
Comparable analyses have so far often depended on large-scale, centralized research or accelerator infrastructure. For many industrial applications, this has not been practical. LDRS is therefore intended to offer a more compact and flexible alternative to conventional large-scale facilities, opening up new ways to make complex structures and material compositions visible without causing damage.
A central technological element of LDRS is the use of high-intensity laser pulses to generate pulsed X-ray and neutron radiation. The interaction of the laser with a specially designed target enables radiation sources that are more compact and more flexibly deployable than traditional large-scale accelerator infrastructures.
The combination of X-rays and neutrons is particularly significant from a technological perspective because the two modalities provide different types of information: while X-rays primarily reveal density and structural information, neutrons can offer additional insights into material composition. This multimodality opens up new possibilities for analyzing sealed, shielded, or otherwise difficult-to-access objects.
Accelerating Industrial Application
"Sourcelight is designed to turn technological innovation into industrial application. To achieve this, we are prioritizing concrete markets, validating use cases together with our partners, and building a platform that is scalable in the long term," says Sebastian Wojczik, Vice President LDRS.
Much like the Apollo space program triggered technological developments far beyond its original objective, laser fusion research is already producing applications today that create tangible benefits in other industries.
About Sourcelight
Sourcelight is the planned spin-off of Focused Energy in the field of laser-driven radiation sources. The company is intended to transfer LDRS technology into industrial applications for non-destructive testing. Its focus is on laser-driven neutron and X-ray sources for the analysis of large components, closed containers, and complex material structures. Sourcelight builds on Focused Energy’s technological development as well as the results of ongoing development and pilot projects.
About Focused Energy
Focused Energy is a German American fusion company headquartered in Darmstadt, with offices in Berlin, Austin, and San Francisco. Founded in 2021 as a spin-off of Technical University Darmstadt, the company develops laser-based fusion technology with the goal of making clean, safe, and virtually inexhaustible energy industrially usable. As the world’s leading company in laser fusion, Focused Energy pursues a consistently industry-oriented approach: building on decades of international fusion research and the technological expertise of its founders, the company combines scientific excellence with the speed and scalability of a privately financed high-tech company. With a team of more than 160 leading scientists and engineers from over 20 nations, Focused Energy is driving the development toward the first commercial laser fusion power plant and is playing a key role in shaping the build-up of a new fusion industry ecosystem. The goal is to transfer fusion technology from research into industrial application in Germany and to build the world’s first laser fusion power plant in Biblis together with partners from industry and science by the mid-2030s.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260610299930/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 10:01:00 CEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom